CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akers Biosciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akers Biosciences, Inc.
201 Grove Road
Phone: (856) 848-8698p:856 848-8698 West Deptford, NJ  08086-2231  United States

This company is no longer actively traded on any major stock exchange.

Business Summary
Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company's primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201812/31/2017YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Interim Chief Financial Officer Howard R.Yeaton 63 10/5/2018 10/5/2018
Independent Director Christopher C.Schreiber 53 8/7/2017 8/7/2017
Independent Director Joshua N.Silverman 48 9/6/2018 9/6/2018
Independent Director Bill J.White 57 8/7/2017 8/7/2017

Business Names
Business Name
AKBS
Akers Biosciences Inc.
Akers Biosciences, Inc.
AKR

General Information
Number of Employees: 28 (As of 12/31/2016)
Outstanding Shares: 12,482,708 (As of 12/28/2018)
Shareholders: 600
Stock Exchange: SEA
Email Address: info@akersbiosciences.com


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, January 19, 2020